Literature DB >> 33537936

Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues.

Clara M Vecchini Rodríguez1,2, Yma Escalona Meléndez2, Jacqueline Flores-Otero3,4.   

Abstract

The potential use of cannabinoids for therapeutic purposes is at the forefront of cannabinoid research which aims to develop innovative strategies to prevent, manage and treat a broad spectrum of human diseases. This chapter briefly reviews the pivotal role of the endocannabinoid system in modulating the central nervous system and its roles on neurodegenerative diseases and brain disorders. Ligand-induced modulation of cannabinoid 1 and 2 receptors to modulate immune response, decrease neurodegeneration and pain are aspects that are also discussed.

Entities:  

Keywords:  CB1R; CB2R; CNS disorders; Cannabinoid ligands; Cannabinoid receptors; Endocannabinoid system; Endogenous ligands; Neurodegenerative diseases; Non-cannabinoid receptors; TRVP1

Mesh：

Substances：

Year:  2021        PMID： 33537936      PMCID： PMC8502072          DOI： 10.1007/978-3-030-61663-2_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  190 in total

Review 1.  Cannabinoids and neuroprotection in basal ganglia disorders.

Authors:  Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Journal:  Mol Neurobiol       Date:  2007-06-23       Impact factor: 5.590

Review 2.  Expression and function of the endocannabinoid system in glial cells.

Authors:  Paola Massi; Marta Valenti; Daniele Bolognini; Daniela Parolaro
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 3.  Traumatic brain injury: can the consequences be stopped?

Authors:  Eugene Park; Joshua D Bell; Andrew J Baker
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

Review 4.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

5.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 6.  Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation?

Authors:  Alan I Faden; David J Loane
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

7.  Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture.

Authors:  J G Netzeband; S M Conroy; K L Parsons; D L Gruol
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

Review 8.  Revised diagnostic criteria of multiple sclerosis.

Authors:  Ron Milo; Ariel Miller
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

Review 9.  Autism, oxytocin and interoception.

Authors:  E Quattrocki; Karl Friston
Journal:  Neurosci Biobehav Rev       Date:  2014-09-30       Impact factor: 8.989

Review 10.  Alzheimer´s Disease in the Perspective of Neuroimmunology.

Authors:  Ricardo B Maccioni; Andrea González; Víctor Andrade; Nicole Cortés; José Pablo Tapia; Leonardo Guzmán-Martínez
Journal:  Open Neurol J       Date:  2018-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.